Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that it has entered into two Cooperative Research and Development Agreements with the Cancer Therapy Evaluation Program of the National Cancer Institute . The CRADAs will evaluate tazemetostat, Epizyme's first-in-class EZH2 inhibitor, and pinometostat, the Company's first-in-class DOT1L inhibitor.

Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that it has entered into two Cooperative Research and Development Agreements with the Cancer Therapy Evaluation Program of the National Cancer Institute . The CRADAs will evaluate tazemetostat, Epizyme's first-in-class EZH2 inhibitor, and pinometostat, the Company's first-in-class DOT1L inhibitor.